Esflurbiprofen was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Sep 28, 2015. It was developed by Taisho and marketed by Taisho and Teijin as Loqoa® in Japan.
Esflurbiprofen is a cyclooxygenase (COX) inhibitor indicated for the treatment of osteoarthritis pain and inflammation.
Loqoa® is available as a patch formulation, containing 40 mg of Esflurbiprofen. The recommended dose is applied to the lesion area once daily. Do not apply more than two patches simultaneously.
Update Date:2016-05-17
Update Date:2016-01-28
Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
---|---|---|---|---|---|---|---|
2015-09-28 | First approval | Loqoa | Osteoarthritis (OA) | Patch | Eq. 40 mg Esflurbiprofen | Taisho |
Update Date:2016-01-22
Update Date:2016-02-21
1. US4188491A.
1. WO2015145163A1.